Introduction FDA’s March 2026 release of the Study Data Technical Conformance Guide (TCG v6.2) has been circulating for a few weeks now. For most teams, it reads like a routine update some language refinements, a few new sections, nothing that demands immediate attention. With the addition of Appendix I, that reading is worth revisiting. FDA’s expectations around SEND are shifting from technical compliance toward review readiness. Those are not the same thing, and the gap bet

Introduction As SEND becomes more established in regulatory submissions to the U.S. FDA, expectations are evolving beyond basic dataset standardization toward greater transparency, expanded domain coverage, and improved support for regulatory review. With SENDIG v4.0 expected to be published in 2026, organizations preparing nonclinical submissions will need to adapt to a broader and more detailed set of requirements. These updates go beyond incremental changes and are likely

Introduction As SEND adoption has matured across regulatory submissions, the focus has gradually shifted beyond technical dataset conversion. Regulatory authorities increasingly evaluate not only whether SEND datasets conform to the standard, but also whether they are transparent, traceable, and suitable for efficient scientific review. Within this evolving environment, validation plays a critical role in ensuring submission quality. While automated validation tools can ident

For Chief Scientific Officers and Regulatory Leaders, SEND is no longer a technical afterthought. It is an operational capability that influences submission readiness, data defensibility, and regulatory confidence across global submissions. As expectations surrounding nonclinical data continue to mature across regions, the question is not simply whether SEND can be delivered — but how SEND dataset preparation and submission support should be structured within the organizatio